middle.news
Radiopharm’s 177Lu-RAD202 Shows Promising Safety and Tumor Uptake in Early HER2+ Trial
9:18am on Monday 20th of April, 2026 AEST
•
Healthcare
Read Story
Radiopharm’s 177Lu-RAD202 Shows Promising Safety and Tumor Uptake in Early HER2+ Trial
9:18am on Monday 20th of April, 2026 AEST
Key Points
177Lu-RAD202 demonstrated meaningful tumor uptake in heavily pre-treated HER2+ patients
No dose-limiting toxicities observed at initial 30 mCi dose cohort
Data Safety and Monitoring Committee approved escalation to 130 mCi dose
Trial targets advanced solid tumors including breast and urothelial cancers
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE